| Name | Title | Contact Details |
|---|
NKMax America is harnessing the power of the body`s immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient`s ability to destroy abnormal cells.
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
Radiant Research is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lynxcom Partners is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
JBJS is a Needham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.